Argus Upgrades AstraZeneca (AZN) to Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Argus upgraded AstraZeneca (NYSE: AZN) from Hold to Buy with a price target of $38.00.
The firm notes management is taking steps to address ricing pressure and generic threats by cutting costs and assembling a strong new drug pipeline, including a promising checkpoint inhibitor to treat various cancers.
They note the shares are trading at 8.5-times their 2017 earnings per ADS forecast, a sharp discount to the average forward multiple of 16.0 for S&P 500 Pharma companies. They view this discount as too steep.
Shares of AstraZeneca closed at $33.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Oppenheimer Upgrades Columbia Property Trust (CXP) to Outperform
- Needham & Company Reiterates Buy on Silicon Motion Technology (SIMO) Following 4Q Report
- Seaport Global Securities Upgrades Sanchez Energy (SN) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Upgrades
Related EntitiesStandard & Poor's, Argus, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!